Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
7/19/2024 | $400.00 | Neutral → Buy | UBS | |
6/26/2024 | $382.00 → $300.00 | Overweight → Equal-Weight | Morgan Stanley | |
6/24/2024 | $335.00 | Neutral | Goldman | |
5/15/2024 | $409.00 → $295.00 | Buy → Hold | Deutsche Bank | |
4/11/2024 | $24.00 | Buy | Craig Hallum | |
3/21/2024 | $400.00 → $360.00 | Positive → Neutral | Susquehanna | |
3/19/2024 | $425.00 | Buy | Guggenheim | |
3/14/2024 | $13.00 | Sector Outperform | Scotiabank |
UBS upgraded Accenture from Neutral to Buy and set a new price target of $400.00
Morgan Stanley downgraded Accenture from Overweight to Equal-Weight and set a new price target of $300.00 from $382.00 previously
Goldman initiated coverage of Accenture with a rating of Neutral and set a new price target of $335.00
SC 13D/A - Tempest Therapeutics, Inc. (0001544227) (Subject)
SC 13D/A - Tempest Therapeutics, Inc. (0001544227) (Subject)
SC 13G/A - Tempest Therapeutics, Inc. (0001544227) (Subject)
4 - HARROW, INC. (0001360214) (Issuer)
4 - Accenture plc (0001467373) (Issuer)
4 - Accenture plc (0001467373) (Issuer)
4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)
4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)
4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)
BRISBANE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced the appointment of Sheldon Mullins as Vice President, Regulatory Affairs. Mr. Mullins' presence on the team builds upon the recent addition of Troy Wagner as Vice President of Quality Assurance, who brought additional late-stage experience to the company. Additionally, in connection with the plan to advance amezalpat into a pivotal study in first-line HCC patients and to reflect their roles in late-stage development, the titles of Darrin Bomba and Henry John
Accenture (NYSE:ACN) has invested, through Accenture Ventures, in Martian, a technology company that has built a patent-pending Large Language Model (LLM) router. For any prompt, Martian's router will find and use the LLM that will give users the best result at the lowest cost. As part of this investment, Accenture plans to integrate Martian's advanced model router offering into its proprietary "switchboard" services that can customize large-language models (LLMs) for specific data sources and use cases for greater impact of AI systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240917605865/en/Accenture has invested, through
Accenture (NYSE:ACN) today announced that Arundhati Chakraborty has been appointed group chief executive of Accenture Operations, effective as of Sept. 1. As clients look to reinvent their operations using tech, data and AI, Chakraborty brings an outstanding track record delivering complex transformations, particularly in her current role leading over 185,000 Accenture people across more than 125 Intelligent Operations Centers, focusing on compressed transformation through analytics, artificial intelligence and automation. With 30 years of industry experience, her ability to shape and implement talent strategy across diverse teams will help Accenture create ever greater value for clients
BRISBANE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced the appointment of Sheldon Mullins as Vice President, Regulatory Affairs. Mr. Mullins' presence on the team builds upon the recent addition of Troy Wagner as Vice President of Quality Assurance, who brought additional late-stage experience to the company. Additionally, in connection with the plan to advance amezalpat into a pivotal study in first-line HCC patients and to reflect their roles in late-stage development, the titles of Darrin Bomba and Henry John
New CEO has driven significant product capabilities, launched new SaaS platform, bolstered the leadership team, and refreshed the brand as company prepares for the AI era CloudBees, one of the world's leading software development platforms, announced today that thousands of developers and industry leaders will convene at DevOps World Virtual 2024 to celebrate 20 years of Jenkins and the future of DevSecOps, and the path forward as the world's businesses invest in cloud transformation and software for the AI era. "The Global 2000 has three key priorities - empower developers, modernize applications securely, and embrace the power of AI in their transformation journey. The reality, however,
Accenture (NYSE:ACN) has invested, through Accenture Ventures, in Martian, a technology company that has built a patent-pending Large Language Model (LLM) router. For any prompt, Martian's router will find and use the LLM that will give users the best result at the lowest cost. As part of this investment, Accenture plans to integrate Martian's advanced model router offering into its proprietary "switchboard" services that can customize large-language models (LLMs) for specific data sources and use cases for greater impact of AI systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240917605865/en/Accenture has invested, through
8-K - HARROW, INC. (0001360214) (Filer)
13F-HR - Accenture plc (0001467373) (Filer)
10-Q - Tempest Therapeutics, Inc. (0001544227) (Filer)
The Nasdaq 100 closed lower by more than 700 points during Wednesday's session. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision. Below is a look at a few recent notable insider sales. For more, check out Benzinga’s insider transactions platform. Bank of America The Trade: Bank of America Corporation (NYSE:BAC) President and CEO Jen Hsun Huang sold a
The Nasdaq 100 closed lower by around 0.4% during Tuesday's session. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision. Below is a look at a few recent notable insider sales. For more, check out Benzinga’s insider transactions platform. NVIDIA The Trade: NVIDIA Corporation (NASDAQ:NVDA) President and CEO Jen Hsun Huang sold a total of 240,000 shares a
Accenture (NYSE:ACN) has outperformed the market over the past 15 years by 3.91% on an annualized basis producing an average annual return of 16.18%. Currently, Accenture has a market capitalization of $207.81 billion. Buying $1000 In ACN: If an investor had bought $1000 of ACN stock 15 years ago, it would be worth $9,404.31 today based on a price of $331.76 for ACN at the time of writing. Accenture's Performance Over Last 15 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and r
New CEO has driven significant product capabilities, launched new SaaS platform, bolstered the leadership team, and refreshed the brand as company prepares for the AI era CloudBees, one of the world's leading software development platforms, announced today that thousands of developers and industry leaders will convene at DevOps World Virtual 2024 to celebrate 20 years of Jenkins and the future of DevSecOps, and the path forward as the world's businesses invest in cloud transformation and software for the AI era. "The Global 2000 has three key priorities - empower developers, modernize applications securely, and embrace the power of AI in their transformation journey. The reality, however,
Accenture (NYSE:ACN) will host a conference call at 8:00 a.m. EDT on Thursday, Sept. 26, 2024 to discuss its fourth-quarter and full-year fiscal 2024 financial results. An earnings news release will be issued before the call. To participate in the teleconference, please dial +1 (877) 692-8955 [+1 (234) 720-6979 outside the U.S., Puerto Rico and Canada] and enter access code 5504138 approximately 15 minutes before the scheduled start of the call. The conference call will also be accessible live via webcast on the Investor Relations section of the Accenture website at www.accenture.com. A replay of the conference call will be available at www.accenture.com and at +1 (866) 207-1041 [+1 (40
Second Quarter 2024 and Recent Selected Highlights: Record revenues of $48.9 million GAAP net loss of $(6.5) million Adjusted EBITDA of $8.8 million Cash and cash equivalents of $71.0 million as of June 30, 2024 IHEEZO® customer unit demand volume increased by 98% from the first quarter of 2024 IHEEZO supply agreements total 24 agreements to date in 2024, including a recent win with the largest and highest volume U.S. retina practice group VEVYE® total prescriptions increased by 212% from the first quarter of 2024 Anterior Segment revenues up over 40% from the first quarter of 2024 Record quarterly revenues from Harrow's ImprimisRx subsidiary Harrow (NASDAQ:HRO